Healthcare Equipment and Supplies
Company Overview of bioLytical Laboratories Inc.
bioLytical Laboratories Inc. develops and manufactures diagnostic products. It provides INSTI, a HIV-1/HIV-2 rapid antibody test used for the detection of antibodies to human immunodeficiency virus type 1 in human whole blood, serum, or plasma. The company sells its products through distributors in Canada and India. bioLytical Laboratories Inc. was founded in 2002 and is based in Richmond, Canada.
1108 - 13351 Commerce Parkway
Richmond, BC V6V 2X7
Founded in 2002
Key Executives for bioLytical Laboratories Inc.
Chief Technical Officer and Vice President
Director of Automation and Materials
Director of Regulatory Affairs
Compensation as of Fiscal Year 2015.
bioLytical Laboratories Inc. Key Developments
bioLytical Laboratories Inc.'s INSTI HIV Test Detects gp41 Specific IgM Antibodies
Sep 3 15
bioLytical Laboratories Inc. announce its study 'Sensitivity of a rapid point of care assay for early HIV antibody detection is enhanced by its affinity for HIV gp41 IgM antibodies has been published in the Journal of Clinical Virology. This study highlights INSTI's ability to detect early HIV infection. BioLytical researchers presented their findings at the 8th annual International AIDS Society Conference, which highlighted early HIV detection using INSTI HIV-1/HIV-2 Antibody Test. The study demonstrated that both recombinant gp41 antigen and protein-A in the HIV screening assay have affinity to human IgM. When IgM was removed from early seroconversion samples that were once reactive with INSTI, the results were non-reactive or barely reactive. The study concluded that INSTI can detect anti-HIV-1 IgM antibodies, which enhances its utility in early HIV diagnosis. Early detection provides significant advantage in the fight against HIV/AIDS. INSTI HIV-1/HIV-2 Antibody Test's ability to detect early HIV antibodies is key to providing earlier diagnosis leading to earlier treatment.
bioLytical Laboratories Develops 60-Second Ebola Testing Kit
Oct 29 14
bioLytical Laboratories has successfully developed a pre-clinical prototype diagnostic test for the rapid detection of antibodies to the Ebola Zaire strain responsible for the current outbreak in West Africa. The prototype is based upon the company's proven, accurate, and highly accepted INSTI rapid test platform, which is capable of providing results in as little as 60 seconds.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries